Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGF inhibitors" to "Category:VEGFR inhbitors") |
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGFR inhbitors" to "Category:VEGFR inhibitors") |
||
Line 12: | Line 12: | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
− | [[Category:VEGFR | + | [[Category:VEGFR inhibitors]] |
[[Category:KIT inhibitors]] | [[Category:KIT inhibitors]] | ||
[[Category:SRC inhibitors]] | [[Category:SRC inhibitors]] |
Revision as of 21:20, 2 February 2018
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Preliminary data
Esophageal cancer; Gastric cancer
- Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016 May 1;34(13):1448-54. Epub 2016 Feb 16. link to original article PubMed